Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-α signaling

Physiological Genomics

Volumn 31, Issue 2, 2007, Pages 343-351

  Zer, Cindy ^b   Sachs, George ^b   Shin, Jai Moo ^a  

^a Membrane Biology   (United States)

^b NONE

Author keywords

Microarray; Rheumatoid arthritis; SB 203580; Synoviocytes

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CHEMOKINE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENE IDENTIFICATION; GENE SEQUENCE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANIMALS; CELLS, CULTURED; CHEMOKINE CXCL2; CHEMOKINES, CXC; CHEMOTAXIS, LEUKOCYTE; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; NEUTROPHILS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35548949968     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00080.2007     Document Type: Article

References (58)

1. Ainola MM, Mandelin JA, Liljestrom MP, Li TF, Hukkanen MV, Konttinen YT. Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1β. Clin Exp Rheumatol 23: 644-650, 2005.
2. Ashwell JD. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol 6: 532-540, 2006.
3. Blades MC, Ingegnoli F, Wheller SK, Manzo A, Wahid S, Panayi GS, Perretti M, Pitzalis C. Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID mice. Arthritis Rheum 46: 824-836, 2002.
4. Chang YW, Chen SC, Cheng EC, Ko YP, Lin YC, Kao YR, Tsay YG, Yang PC, Wu CW, Roffler SR. CD13 (aminopeptidase N) can associate with tumor-associated antigen L6 and enhance the motility of human lung cancer cells. Int J Cancer 116: 243-252, 2005.
5. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364: 229-233, 1995.
6. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 162: 2163-2168, 1985.
7. Eggert M, Schulz M, Neeck G. Molecular mechanisms of glucocorticoid action in rheumatic autoimmune diseases. J Steroid Biochem Mol Biol 77: 185-191, 2001.
8. Espersen GT, Vestergaard M, Ernst E, Grunnet N. Tumour necrosis factor α and interleukin-2 in plasma from rheumatoid arthritis patients in relation to disease activity. Clin Rheumatol 10: 374-376, 1991.
9. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144: 3347-3353, 1990.
10. Fisker S, Kudahl K, Sonne O. Isolation of rat peritoneal mononuclear and polymorphonuclear leucocytes on discontinuous gradients of Nycodenz. J Immunol Methods 133: 31-38, 1990.
11. Gallagher J, Howlin J, McCarthy C, Murphy EP, Bresnihan B, FitzGerald O, Godson C, Brady HR, Martin F. Identification of Naf1/ABIN-1 among TNF-α-induced expressed genes in human synoviocytes using oligonucleotide microarrays. FEBS Lett 551: 8-12, 2003.
12. Goedert M, Cuenda A, Craxton M, Jakes R, Cohen P. Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases. EMBO J 16: 3563-3571, 1997.
13. Gum RJ, McLaughlin MM, Kumar S, Wang Z, Bower MJ, Lee JC, Adams JL, Livi GP, Goldsmith EJ, Young PR. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem 273: 15605-15610, 1998.
14. Han SK, Jeon SJ, Miyazawa K, Yi SY, Yoo YS. Enhancement of anti-inflammatory tendency by SB203580, p38α specific inhibitor, in human fibroblast-like synoviocyte cell line, MH7A. Rheumatol Int 26: 972-978, 2006.
15. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 291: 124-130, 1999.
16. Hansen IB, Ellingsen T, Hornung N, Poulsen JH, Lottenburger T, Stengaard-Pedersen K. Plasma level of CXC-chemokine CXCL12 is increased in rheumatoid arthritis and is independent of disease activity and methotrexate treatment. J Rheumatol 33: 1754-1759, 2006.
17. Holt I, Cooper RG, Denton J, Meager A, Hopkins SJ. Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol 31: 725-733, 1992.
18. Huang Z, Ducharme Y, Macdonald D, Robichaud A. The next generation of PDE4 inhibitors. Curr Opin Chem Biol 5: 432-438, 2001.
19. Jeong JG, Kim JM, Cho H, Hahn W, Yu SS, Kim S. Effects of IL-1β on gene expression in human rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 324: 3-7, 2004.
20. Kao YR, Shih JY, Wen WC, Ko YP, Chen BM, Chan YL, Chu YW, Yang PC, Wu CW, Roffler SR. Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res 9: 2807-2816, 2003.
21. Korb A, Tohidast-Akrad M, Cetin E, Axmann R, Smolen J, Schett G. Differential tissue expression and activation of p38 MAPK α, β, γ and δ isoforms in rheumatoid arthritis. Arthritis Rheum 54: 2745-2756, 2006.
22. Kumar S, Jiang MS, Adams JL, Lee JC. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun 263: 825-831, 1999.
23. Laufer SA, Striegel HG, Wagner GK. Imidazole inhibitors of cytokine release: probing substituents in the 2 position. J Med Chem 45: 4695-4705, 2002.
24. Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, Kim SY. Transglutaminase 2 induces nuclear factor-κB activation via a novel pathway in BV-2 microglia. J Biol Chem 279: 53725-53735, 2004.
25. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746, 1994.
26. Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38α protein. Curr Med Chem 12: 2979-2994, 2005.
27. Lehmann J, Jungel A, Lehmann I, Busse F, Biskop M, Saalbach A, Emmrich F, Sack U. Grafting of fibroblasts isolated from the synovial membrane of rheumatoid arthritis (RA) patients induces chronic arthritis in SCID mice - A novel model for studying the arthritogenic role of RA fibroblasts in vivo. J Autoimmun 15: 301-313, 2000.
28. Lin Z, Crockett DK, Jenson SD, Lim MS, Elenitoba-Johnson KS. Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells. Mol Cell Proteomics 3: 820-833, 2004.
29. Moreland LW. Biologic therapies on the horizon for rheumatoid arthritis. J Clin Rheumatol 10: S32-S39, 2004.
30. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, Gay S. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 149: 1607-1615, 1996.
31. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36, 2002.
32. Proost P, Struyf S, Loos T, Gouwy M, Schutyser E, Conings R, Ronsse I, Parmentier M, Grillet B, Opdenakker G, Balzarini J, Van Damme J. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res Ther 8: R107, 2006.
33. Sack U, Hirth A, Funke B, Wiedemeyer K, Lange F, Troltzsch M, Tannapfel A, Gebhardt R, Emmrich F, Lehmann J. A novel model of fibroblast-mediated cartilage destruction. Scand J Immunol 61: 18-28, 2005.
34. Scaife S, Brown R, Kellie S, Filer A, Martin S, Thomas AM, Bradfield PF, Amft N, Salmon M, Buckley CD. Detection of differentially expressed genes in synovial fibroblasts by restriction fragment differential display. Rheumatology (Oxford) 43: 1346-1352, 2004.
35. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, Steiner G. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43: 2501-2512, 2000.
36. Schlenk J, Lorenz HM, Haas JP, Herrmann M, Hohenberger G, Kalden JR, Rollinghoff M, Beuscher HU. Extravasation into synovial tissue induces CCL20 mRNA expression in polymorphonuclear neutrophils of patients with rheumatoid arthritis. J Rheumatol 32: 2291-2298, 2005.
37. Schramm R, Thorlacius H. Staphylococcal enterotoxin B-induced acute inflammation is inhibited by dexamethasone: important role of CXC chemokines KC and macrophage inflammatory protein 2. Infect Immun 71: 2542-2547, 2003.
38. Sers C, Emmenegger U, Husmann K, Bucher K, Andres AC, Schafer R. Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. J Cell Biol 136: 935-944, 1997.
39. Shields JM, Rogers-Graham K, Der CJ. Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem 277: 9790-9799, 2002.
40. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 48: 2155-2162, 2003.
41. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2: 473-488, 2003.
42. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Semin Arthritis Rheum 26: 435-446, 1996.
43. Taberner M, Scott KF, Weininger L, Mackay CR, Rolph MS. Overlapping gene expression profiles in rheumatoid fibroblast-like synoviocytes induced by the proinflammatory cytokines interleukin-1β and tumor necrosis factor. Inflamm Res 54: 10-16, 2005.
44. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 43: 2619-2633, 2000.
45. Tanaka I, Morikawa M, Okuse T, Shirakawa M, Imai K. Expression and regulation of WISP2 in rheumatoid arthritic synovium. Biochem Biophys Res Commun 334: 973-978, 2005.
46. Tarrant TK, Patel DD. Chemokines and leukocyte trafficking in rheumatoid arthritis. Pathophysiology 13: 1-14, 2006.
47. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 49: 665-667, 1990.
48. Tian B, Nowak DE, Jamaluddin M, Wang S, Brasier AR. Identification of direct genomic targets downstream of the nuclear factor-κB transcription factor mediating tumor necrosis factor signaling. J Biol Chem 280: 17435-17448, 2005.
49. Trivedi P, Edwards JW, Wang J, Gadbury GL, Srinivasasainagendra V, Zakharkin SO, Kim K, Mehta T, Brand JP, Patki A, Page GP, Allison DB. HDBStat!: a platform-independent software suite for statistical analysis of high dimensional biology data. BMC Bioinformatics 6: 86, 2005.
50. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor κB. J Clin Invest 101: 1163-1174, 1998.
51. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 10: 45-65, 2003.
52. Wernicke D, Seyfert C, Gromnica-Ihle E, Stiehl P. The expression of collagenase 3 (MMP-13) mRNA in the synovial tissue is associated with histopathologic type II synovitis in rheumatoid arthritis. Autoimmunity 39: 307-313, 2006.
53. Westra J, Limburg PC, de Boer P, van Rijswijk MH. Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis 63: 1453-1459, 2004.
54. Wibulswas A, Croft D, Bacarese-Hamilton I, McIntyre P, Genot E, Kramer IM. The CD44v7/8 epitope as a target to restrain proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Am J Pathol 157: 2037-2044, 2000.
55. Wolpe SD, Sherry B, Juers D, Davatelis G, Yurt RW, Cerami A. Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci USA 86: 612-616, 1989.
56. Zhang HG, Hyde K, Page GP, Brand JP, Zhou J, Yu S, Allison DB, Hsu HC, Mountz JD. Novel tumor necrosis factor α-regulated genes in rheumatoid arthritis. Arthritis Rheum 50: 420-431, 2004.
57. Zimmermann T, Kunisch E, Pfeiffer R, Hirth A, Stahl HD, Sack U, Laube A, Liesaus E, Roth A, Palombo-Kinne E, Emmrich F, Kinne RW. Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture - primary culture cells markedly differ from fourth-passage cells. Arthritis Res 3: 72-76, 2001.
58. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 54: 3399-3407, 2006.